RESUMEN
Real-world studies are relevant to complement clinical trials on novel antiviral therapies against chronic hepatitis C; however, clinical practice data are currently limited. This study investigated effectiveness and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r)±dasabuvir (DSV)±ribavirin (RBV) for treatment of HCV genotype (GT) 1 and GT4 infection in a large real-world cohort. The German Hepatitis C Registry is an observational cohort study prospectively collecting clinical practice data on direct-acting antiviral therapies. Patients with GT1/4 infection treated with OBV/PTV/r±DSV±RBV were analysed. Effectiveness was assessed by sustained virologic response in 558 patients who reached post-treatment week 12 (SVR12). Safety is reported in 1017 patients who initiated treatment. Of the patients, 892 (88%) had GT1 and 125 (12%) had GT4 infection. Prior treatment experience and cirrhosis were reported in 598 (59%) and 228 (22%) patients, respectively. Overall, SVR12 (mITT) was 96% (486/505) in GT1- and 100% (53/53) in GT4 patients. SVR12 rates were high across subgroups including patients with cirrhosis (95%, 123/129), patients with moderate to severe renal impairment (100%, 34/34), and subgroups excluded from registrational trials like patients ≥70 years (96%, 64/67) and failures to prior protease inhibitor treatment (96%, 46/48). Adverse events (AEs) and serious AEs were reported in 52% (525/1017) and 2% (21/1017) of patients, respectively, and led to treatment discontinuation in 1.5% (15/1017) of patients. OBV/PTV/r±DSV±RBV was effective and generally well tolerated for treatment of HCV infection in clinical practice.
Asunto(s)
Anilidas/administración & dosificación , Carbamatos/administración & dosificación , Hepatitis C Crónica/tratamiento farmacológico , Hepatitis C Crónica/virología , Compuestos Macrocíclicos/administración & dosificación , Ritonavir/administración & dosificación , Sulfonamidas/administración & dosificación , Uracilo/análogos & derivados , 2-Naftilamina , Adulto , Anciano , Anilidas/efectos adversos , Carbamatos/efectos adversos , Estudios de Cohortes , Ciclopropanos , Quimioterapia Combinada , Femenino , Genotipo , Alemania , Hepacivirus/genética , Hepatitis C Crónica/complicaciones , Hepatitis C Crónica/diagnóstico , Humanos , Lactamas Macrocíclicas , Cirrosis Hepática/diagnóstico , Cirrosis Hepática/etiología , Compuestos Macrocíclicos/efectos adversos , Masculino , Persona de Mediana Edad , Prolina/análogos & derivados , Ritonavir/efectos adversos , Índice de Severidad de la Enfermedad , Sulfonamidas/efectos adversos , Resultado del Tratamiento , Uracilo/administración & dosificación , Uracilo/efectos adversos , Valina , Carga ViralRESUMEN
In 2014, the first interferon-free treatment options for chronic Hepatitis C (CHC) became available in Europe introducing a new era of highly effective and well tolerated oral treatment options for CHC. The data from the cross-sectional study CURRENT-C highlights the epidemiological characteristics of patients with CHC in Germany. During the period that the study was conducted, the approval of the combination drugs for the treatment of CHC was imminent.Between June and November 2014, 1471 CHC-patients not receiving anti-HCV treatment were included nationwide in 40 German centers specializing in viral hepatitis. The mean age was 52.4 years with 41.2â% of the patients being female. Presumed route of infection in male patients was most frequently drug use (46.2â%) and blood products in females (22.8â%). The route of infection was unknown in 28.2â% of male and 43.1â% of female patients. Compared to male patients, female patients were older (55.6 vs. 50.1 years) and longer diagnosed with HCV (18 vs. 15 years). First language of the patients was most frequently German (72.2â%), followed by Russian (14.2â%), and Polish (2.9â%). HCV genotype (GT) 1 was found in 73.8â% (1a 29.0â%, 1b 38.4â%), GT2 in 3.5â%, GT3 in 18.3â%, GT4 in 4.2â%, GT5 in 0.2â%, and GT6 in 0.3â%. Liver cirrhosis was diagnosed in 15.7â% of the patients (17.1â% male, 13.7â% female). 43.2â% of the patients had already received HCV treatment, most frequently dual therapy with pegIFN + RBV (75.8â%) or triple therapy with telaprevir or boceprevir (20.3â%). Compared to treatment-naïve patients, pretreated HCV patients were older (55.1 vs. 50.3 years) and more frequently had liver cirrhosis as clinical diagnosis (22.2â% vs. 10.8â%). Patients scheduled for HCV treatment within the next 3 months had higher rates of pre-treatment (49.4â% vs. 37.0â%), and liver cirrhosis (21.4â% vs. 10.0â%).Compared to epidemiological data of Hüppe et al. 1 from 2003 to 2006, Klass et al. 2 stated in 2012 in a comparable setting that the German CHC population were older and had more advanced liver disease. The current data seem to support this ongoing trend towards more difficult to treat patients with an urgent need for new treatment options.
Asunto(s)
Antivirales/administración & dosificación , Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Hepatitis C Crónica/tratamiento farmacológico , Hepatitis C Crónica/epidemiología , Pautas de la Práctica en Medicina/estadística & datos numéricos , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Combinación de Medicamentos , Femenino , Alemania/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Factores de Riesgo , Distribución por SexoRESUMEN
Matrix metalloproteinase-13 (MMP-13) is a zinc-dependent protease responsible for the cleavage of type II collagen, the major structural protein of articular cartilage. Degradation of this cartilage matrix leads to the development of osteoarthritis. We previously have described highly potent and selective carboxylic acid containing MMP-13 inhibitors; however, nephrotoxicity in preclinical toxicology species precluded development. The accumulation of compound in the kidneys mediated by human organic anion transporter 3 (hOAT3) was hypothesized as a contributing factor for the finding. Herein we report our efforts to optimize the MMP-13 potency and pharmacokinetic properties of non-carboxylic acid leads resulting in the identification of compound 43a lacking the previously observed preclinical toxicology at comparable exposures.
Asunto(s)
Metaloproteinasa 13 de la Matriz/efectos de los fármacos , Inhibidores de la Metaloproteinasa de la Matriz/síntesis química , Inhibidores de la Metaloproteinasa de la Matriz/farmacología , Osteoartritis/tratamiento farmacológico , Pirimidinas/síntesis química , Pirimidinas/farmacología , Tetrazoles/síntesis química , Tetrazoles/farmacología , Animales , Cartílago Articular/efectos de los fármacos , Cartílago Articular/patología , Colagenasas/efectos de los fármacos , Perros , Diseño de Fármacos , Humanos , Riñón/metabolismo , Macaca fascicularis , Masculino , Inhibidores de la Metaloproteinasa de la Matriz/toxicidad , Modelos Moleculares , Transportadores de Anión Orgánico Sodio-Independiente/metabolismo , Unión Proteica , Ratas , Ratas Sprague-Dawley , Relación Estructura-ActividadRESUMEN
The integrin alpha(v)beta(3), vitronectin receptor, is expressed in a number of cell types and has been shown to mediate adhesion of osteoclasts to bone matrix, vascular smooth muscle cell migration, and angiogenesis. We recently disclosed the discovery of a tripeptide Arg-Gly-Asp (RGD) mimic, which has been shown to be a potent inhibitor of the integrin alpha(v)beta(3) and has excellent anti-angiogenic properties including its suppression of tumor growth in animal models. In other investigations involving RGD mimics, only compounds containing the S-isomers of the beta-amino acids have been shown to be potent. We were surprised to find the potencies of analogs containing enantiomerically pure S-isomers of beta-amino acids which were only marginally better than the corresponding racemic mixtures. We therefore synthesized RGD mimics containing R-isomers of beta-amino acids and found them to be relatively potent inhibitors of alpha(v)beta(3). One of the compounds was examined in tumor models in mice and has been shown to significantly reduce the rate of growth and the size of tumors.
Asunto(s)
Aminoácidos/química , Antineoplásicos/química , Antineoplásicos/farmacología , Integrina alfaVbeta3/antagonistas & inhibidores , Imitación Molecular , Oligopéptidos/química , Oligopéptidos/farmacología , Aminoácidos/síntesis química , Animales , Antineoplásicos/farmacocinética , Neoplasias del Colon , Hipercalcemia/inducido químicamente , Isomerismo , Melanoma , Ratones , Ratones Endogámicos , Oligopéptidos/farmacocinética , Neoplasias Cutáneas , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
The present study examines the effects that temporal and spatial averagings due to finite size and finite response time of pressure transducers have on the pressure measurements in blast wave flow fields generated by milligram charges of silver azide. In such applications, the characteristic time and length scales of the physical process are of the same order of magnitude as the temporal and spatial characteristics of the transducer. The measured pressure values will then be spatially and temporally averaged, and important parameters for the assessment of blast effects may not be properly represented in the measured trace. In this study, face-on and side-on pressure transducer setups are considered. In the experiments, face-on and side-on readings at the same distance from the charge as well as time-resolved optical visualization of the whole flow field are obtained simultaneously for the same explosive event. The procedure of data extraction from the experimental pressure traces is revisited and discussed in detail. In the numerical modeling part of the study, numerical blast flow fields are generated using an Euler flow solver. A numerical pressure transducer model is developed to qualitatively simulate the averaging effects. The experimental and numerical data show that the results of pressure measurements in experiments with small charges must be used with great caution. The effective averaging of the pressure signal may lead to a significant underestimation of blast wave intensities. The side-on setup is especially prone to this effect. The face-on setup provides results close to those obtained from optical records only if the pressure transducer is sufficiently remote from the charge.
RESUMEN
Identification of additional prognostic factors besides karyotype is important for the improvement of the risk adapted treatment strategies in acute myeloid leukemia (AML). The aim of this study was to investigate whether other factors besides karyotype could be used as a prognostic tool in newly diagnosed AML. Biological and disease related established and potential prognostic factors were retrospectively analysed in 124 consecutive AML patients treated between 1993 and 2002 at the University hospital Rostock (Germany). One hundred patients received a potential curative intensive chemotherapy (81%), of whom 28 received an allogeneic HSCT at some point of their treatment course, 17 patients (14%) received palliative therapies and 7 patients (5%) received supportive care only. In patients that received potential curative therapies LDH >or=2000 U/l, WBC >50 GPT/l, CD34 surface expression on the AML blasts, secondary AML, unfavorable karyotype and no allogeneic HSCT at some point of treatment course were associated with unfavorable prognosis. However, in the multivariate risk factor analyses only unfavorable karyotype (p=0.012), CD34 positivity of AML blasts (p=0.046), no allogeneic HSCT (p=0.008) and first diagnosis after 1997 (p=0.025) were independent unfavourable prognostic factors. In conclusion, karyotype and CD34 expression are independent prognostic markers in newly diagnosed AML. Furthermore, receiving an allogeneic HSCT at some point of the treatment course seems to be of benefit for AML patients.
Asunto(s)
Antígenos CD34/metabolismo , Biomarcadores de Tumor/análisis , Aberraciones Cromosómicas , Leucemia Mieloide/genética , Leucemia Mieloide/mortalidad , Enfermedad Aguda/terapia , Adulto , Factores de Edad , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Supervivencia sin Enfermedad , Citometría de Flujo , Trasplante de Células Madre Hematopoyéticas , Humanos , Cariotipificación , Leucemia Mieloide/terapia , Persona de Mediana Edad , Análisis Multivariante , Cuidados Paliativos , Pronóstico , Inducción de Remisión , Estudios Retrospectivos , Factores de Riesgo , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
The intrinsic dc conductivity of long, individual lambda phage dsDNA molecules has been investigated by ultrasensitive low current-voltage-spectroscopy (IV) under ambient conditions and controlled low humidity inert gas atmosphere on microfabricated metal-insulator-metal gap structures. We found a strong dependence of the measured conductivity on the apparent humidity, which we attribute to capillary condensation of water to the immobilized DNA molecules, giving rise to additional ionic currents. Additional IV-spectroscopy experiments under controlled argon atmosphere always revealed a significant drop in electrical conductivity to 4 x 10(-15)AV(-1)microm(-1), indicating almost no considerable contribution of electrical long range charge transport.
Asunto(s)
Bacteriófago lambda/genética , ADN Viral/análisis , ADN Viral/química , Electroquímica/métodos , Electrodos , Análisis Espectral/métodos , ADN Viral/ultraestructura , Conductividad EléctricaRESUMEN
OBJECTIVE: Bone marrow-derived adult stem cells may be able to regenerate infarcted myocardium. We initiated a phase-I study of autologous stem cell transplantation in patients undergoing coronary artery bypass grafting. METHODS: Inclusion criteria were: acute myocardial infarction > 10 days ago; presence of a distinct area of infarcted and akinetic myocardium; CABG indicated to treat ischemia of other LV wall areas. Stem cells were isolated from bone marrow using a ferrite-conjugated AC133 antibody, and were injected in the infarct border zone during the CABG operation. RESULTS: To date, 12 patients were treated without major complications. There is no evidence of new ventricular arrhythmia or neoplasia. Scintigraphic imaging demonstrated significantly improved local perfusion in the stem cell-treated infarct area. LV dimensions (LVEDV 140 +/- 38 ml vs. 124 +/- 30 ml, p = 0.004, paired t-test) and LV ejection fraction (39.7 +/- 9 % vs. 48.7 +/- 6 %, p = 0.007) have improved. CONCLUSIONS: Bone marrow stem cell transplantation for myocardial regeneration can be safely performed in humans. There is evidence of improved revascularization and contractility of infarct areas, but controlled studies are needed to clearly determine the clinical benefit.
Asunto(s)
Puente de Arteria Coronaria , Trasplante de Células Madre Hematopoyéticas , Infarto del Miocardio/cirugía , Anciano , Humanos , Masculino , Persona de Mediana Edad , Contracción Miocárdica , Miocardio/metabolismo , Periodo Posoperatorio , Control de Calidad , Regeneración , Trasplante Autólogo , Función Ventricular IzquierdaRESUMEN
The graft vs. leukemia (GVL) effect is one of the most important factors of anti-tumor activity after allogeneic hematopoetic stem cell transplants (alloSCT). Its effectiveness depends mainly on the tumor biology as well as the tumor burden. Patients with a high tumor burden may not respond to GVL-effect despite otherwise sensitive biology. Campath-1H is known as an effective treatment of chronic lymphocytic leukemia (CLL). Due to its ability to induce profound immunosuppression, it has also been used as part of conditioning regimens before alloSCT. We report a patient, who received campath-1H in combination with docetaxel for treatment of chemotherapy and donor lymphocyte infusion resistant CLL after alloSCT, who developed shortly after discontinuation of treatment with campath-1H severe eosinophilia of the peripheral blood and typical clinical as well as histological signs of cutaneous chronic graft vs. host disease followed by complete clearance of CLL. The clinical course demonstrates the impact of the tumor burden on the GVL-effect, as well as the effectiveness of campath-1H in the presence chemo-resistance in a patient with CLL. Furthermore, the GVL effect was not abrogated by the use of campath-1H.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Antineoplásicos/uso terapéutico , Antineoplásicos/uso terapéutico , Enfermedad Injerto contra Huésped/diagnóstico , Leucemia Linfocítica Crónica de Células B/tratamiento farmacológico , Trasplante de Células Madre/efectos adversos , Alemtuzumab , Anticuerpos Monoclonales Humanizados , Humanos , Masculino , Persona de Mediana Edad , Recurrencia , Enfermedades de la Piel/diagnóstico , Enfermedades de la Piel/etiología , Trasplante Homólogo , Resultado del TratamientoRESUMEN
Intermittently occuring hemolytic anemia can be the expression of paroxysmal nocturnal hemoglobinuria (PNH). Diagnosis is made via the detection of decreased resistance of the erythrocytes to acidified serum or osmotic hemolysis. Furthermore, diagnostic proof is provided by the cytometric detection of several erythrocyte populations caused by the altered expression of an anchor protein (PIG-A protein) of the cell membrane. This report is of a case where "black morning urine" has been in existence for more than 10 years and in which the additional occurrence of icterus led to the diagnosis. The patient's spleen had been removed in 1964 because of idiopathic thrombopenia, in retrospect, however, thrombopenia within the framework of PNH should be considered.
Asunto(s)
Hemoglobinuria Paroxística/diagnóstico , Antígenos CD/sangre , Hemoglobinuria Paroxística/complicaciones , Hemólisis , Humanos , Receptores de Lipopolisacáridos/sangre , Proteínas de la Membrana/sangre , Persona de Mediana Edad , Trombocitopenia/etiologíaRESUMEN
The use of ultrasonic instruments to remove PMMA bone cement during revision hip arthroplasty results in the production of fumes. These emissions were analysed under standardized laboratory conditions, when it was found that the MMA concentration measured was only 1/10th of the MAC value. In terms of occupational safety, the MMA fumes emitted may therefore be considered non-hazardous for the medical personnel.
Asunto(s)
Contaminantes Ocupacionales del Aire/análisis , Cementos para Huesos/análisis , Prótesis de Cadera , Polimetil Metacrilato/análisis , Terapia por Ultrasonido , Monitoreo del Ambiente , Cromatografía de Gases y Espectrometría de Masas , Humanos , Quirófanos , ReoperaciónRESUMEN
There is little information available regarding the role of inflammatory cells in the pathogenesis of chronic pancreatitis. Therefore, we analyzed the local cytokine profile and infiltrating lymphocytes in a rat model of chronic pancreatitis. Experimental pancreatitis was induced by a single intravenous application of dibultyltin dichloride (DBTC). During a time course of two months we observed the mRNA expression of cytokines using competitive RT-PCR. Lymphocytes were characterized by immunohistochemistry, FACS analysis, and the lymphocyte proliferation test. IL-1beta, IL-6, IL-5, and IL-10 were immediately up-regulated in the acute phase of disease, while lymphocyte-restricted expression of IL-2, IL-2R, and IFN-y was only found in the chronic course. Among the infiltrating lymphocytes, CD4+ cells dominated, but during the chronic process there was an increase of CD8+ cells, resulting in a reduced CD4/CD8 ratio. Mitogen-induced activation of isolated mesenteric lymph node cells increased during the chronic inflammation. Our results suggest that in experimental pancreatitis acute inflammatory reactions are followed by a T-lymphocyte-mediated process.
Asunto(s)
Citocinas/metabolismo , Linfocitos/patología , Páncreas/patología , Pancreatitis/inmunología , Animales , Relación CD4-CD8 , Enfermedad Crónica , Citocinas/genética , Inmunohistoquímica , Interferón gamma/metabolismo , Interleucinas/metabolismo , Activación de Linfocitos , Linfocitos/metabolismo , Masculino , Compuestos Orgánicos de Estaño , Páncreas/metabolismo , Pancreatitis/inducido químicamente , Pancreatitis/patología , ARN Mensajero/metabolismo , Ratas , Ratas Endogámicas Lew , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Linfocitos T/fisiología , Factores de Tiempo , Regulación hacia ArribaRESUMEN
Ten consecutive patients in our unit who had failed to mobilize a sufficient stem cell yield after either an initial or several mobilization regimens received high-dose etoposide phosphate (1500-2000 mg/m2) followed by granulocyte colony-stimulating factor (G-CSF; 10 micrograms/kg per day) to stimulate mobilization. Eight of the ten patients were apheresed. A median of 2.1 x 10(6) CD34+/kg (range 0-5.2) was collected. The number of CD34+ cells/microliter peripheral blood (pB) was significantly increased compared to the first-line mobilization [median 13.0 (range 2.68-29) versus median 4.76 (range 1.36-12); P < 0.05]. Besides hematotoxicity and four cases of infection (WHO grade 3), no major side effects were seen. The median duration of neutropenia was short (5 days, range 0-10), which is important in heavily pretreated patients. These results indicate that high-dose etoposide phosphate with G-CSF is safe, well tolerated, and may be effective in peripheral blood stem cell (PBSC) mobilization in patients who had previously failed to mobilize.
Asunto(s)
Etopósido/administración & dosificación , Etopósido/farmacocinética , Factor Estimulante de Colonias de Granulocitos/farmacología , Factor Estimulante de Colonias de Granulocitos/farmacocinética , Movilización de Célula Madre Hematopoyética , Compuestos Organofosforados/administración & dosificación , Compuestos Organofosforados/farmacocinética , Adulto , Coriocarcinoma/tratamiento farmacológico , Ciclofosfamida/farmacología , Relación Dosis-Respuesta a Droga , Etopósido/análogos & derivados , Etopósido/toxicidad , Femenino , Germinoma/tratamiento farmacológico , Enfermedad de Hodgkin/tratamiento farmacológico , Humanos , Lactante , Linfoma no Hodgkin/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Compuestos Organofosforados/toxicidad , Equivalencia Terapéutica , Acondicionamiento Pretrasplante , Irradiación Corporal TotalAsunto(s)
Transfusión de Eritrocitos , Leucaféresis , Leucocitos , Infecciones Bacterianas/prevención & control , Infecciones Bacterianas/transmisión , Transfusión de Eritrocitos/efectos adversos , Filtración , Humanos , Leucocitos/citología , Leucocitos/microbiología , Virosis/prevención & control , Virosis/transmisiónRESUMEN
The ability to generate reactive oxygen species, the so-called oxidative burst, is essential for neutrophils to kill infectious micro-organisms. Flow cytometry was used to study oxidative burst prior to, during, and after cytostatic therapy. Seven patients were treated according to the DexaBEAM regimen with 12 cycles monitored. Four patients were treated according to the B-NHL regimen in which nine cycles were monitored. Ten healthy volunteers were chosen as a control group without any treatment. Neutrophils were collected from heparinized peripheral blood and were stimulated by phorbol-12-myristate-13-acetate (PMA), N-formyl-methionyl-leucyl-phenylalanine (FMLP), and Escherichia coli. The oxidative burst was estimated by the amount of nonfluorescent dihydrorhodamine 123 converted to green fluorescent rhodamine 123. Measurements were done daily. The FMLP-induced burst was enhanced in patients before therapy as compared with the control group, whereas PMA-induced burst was decreased slightly. E. coli-, FMLP-, and PMA-induced oxidative burst decreased in both groups during cytostatic therapy. E. coli-induced burst increased again within 2 days of G-CSF treatment in vivo. FMLP-induced burst increased in the B-NHL group but decreased in the DexaBEAM group. In patients who have recovered from leukopenia the oxidative burst is still partly suppressed. PMA-induced oxidative burst measured at the start of therapy correlates with infectious complications. Thus, PMA-induced burst may be used as a simple method for evaluating the individual risk of infections during therapy. The results demonstrate the modulating effect of cytostatic drugs on the oxidative burst and may explain why some patients suffer from severe bacterial infections although the total number of granulocytes is normal.
Asunto(s)
Antineoplásicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Estallido Respiratorio/efectos de los fármacos , Adulto , Carmustina/administración & dosificación , Citarabina/administración & dosificación , Dexametasona/administración & dosificación , Escherichia coli/fisiología , Etopósido/administración & dosificación , Femenino , Factor Estimulante de Colonias de Granulocitos/farmacología , Factor Estimulante de Colonias de Granulocitos/fisiología , Humanos , Linfoma de Células B/tratamiento farmacológico , Linfoma no Hodgkin/tratamiento farmacológico , Masculino , Melfalán/administración & dosificación , Persona de Mediana Edad , N-Formilmetionina Leucil-Fenilalanina/farmacología , Pronóstico , Acetato de Tetradecanoilforbol/farmacologíaRESUMEN
OBJECTIVE: To evaluate the function of T cells in chronic myeloid leukemia (CML). METHODS: Interleukin-1 beta (IL-1 beta), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF alpha), and granulocyte macrophage-colony stimulating factor (GM-CSF) gene expressions were investigated by reverse transcription polymerase chain reaction (RT-PCR) assay in fluorescence active cell sorter (FACS) sorted peripheral blood CD2+/CD56-T cells from 12 CML patients, 10 meylodysplastic syndrome (MDS) patients and 7 normal individuals. RESULTS: TNF alpha mRNA was transcribed in T cells from all of the CML, MDS and normal individuals. IL-1 beta mRNA was transcribed in T cells from 10 CML, 9 MDS and 6 normal individuals. Low levels of IL-2 and IL-4 mRNA were detected in 5 CML patients. IL-3, IL-6 and GM-CSF mRNA were undetectable in all samples. CONCLUSION: IL-4 and IL-2 were expressed abnormally in T cells of CML.
Asunto(s)
Citocinas/genética , Leucemia Mielógena Crónica BCR-ABL Positiva/inmunología , Linfocitos T/fisiología , Adulto , Humanos , Interleucina-1/genética , ARN Mensajero/análisis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factor de Necrosis Tumoral alfa/genéticaRESUMEN
BACKGROUND: A new method for the detection of residual aneuploid leukemic cells in bone marrow by flow cytometry is described. This method is based on the analysis of FCM derived list-mode-datasets with a new software called "Continuous Gating". The program is able to decrease the detection level of aneuploid tumor cells by analyzing groups of cells with comparable antigen density and scatter properties. METHODS: Aneuploid acute lymphocytic leukemia cells with a known CD34 expression were diluted with diploid bone marrow cells to a concentration of 10, 1, 0.1, 0.05, and 0.01%. Each sample was measured in a FACScan flow cytometer, after staining with CD34 Moab and propidium iodide. Listmode-data were analyzed with the new "Windows"-based "Continuous Gating" software. A gate was set in the DNA parameter, defining the channels in which the aneuploid G0/G1-peak of possible residual tumor-cells should be found. Ten thousand overlapping gates of size 200 x 200 channels (out of 1,023 x 1,023 channels) were set automatically by the program into the side-scatter (SSC)/CD34 dot-plot, calculating the percentage of aneuploid G0/G1-phase cells for every specific gate. RESULTS: The results are plotted in a contour-plot. In dot-plot gates with less than 20 cells, the calculation of the percentage of aneuploid cells was declared invalid and the area in the contour-plot was marked. Detection of residual aneuploid cells, based on a defined expression of CD34 and granularity (SSC), was possible down to a contamination of 0.1%. CONCLUSIONS: The new "Continuous Gating" software can be used for the automated detection of aneuploid leukemic cells, if the density of a certain surface-marker is slightly different from normal cells.
Asunto(s)
ADN de Neoplasias/análisis , Citometría de Flujo/métodos , Leucemia-Linfoma Linfoblástico de Células Precursoras/diagnóstico , Leucemia-Linfoma Linfoblástico de Células Precursoras/patología , Adulto , Aneuploidia , Antígenos CD19/análisis , Antígenos CD34/análisis , Biomarcadores de Tumor , Células de la Médula Ósea/química , Humanos , Procesamiento de Imagen Asistido por Computador/métodos , Masculino , Neprilisina/análisisRESUMEN
Fludarabine (F-ara-A), an adenine nucleoside analog with efficacy in B-cell chronic lymphocytic leukemia (B-CLL), has also been shown to have a long-lasting suppressive effect on T lymphocytes. In heterogeneous clinical samples, apoptosis cannot be detected by standard methods in small cellular subsets. We developed, therefore, a combined assay of in situ end-labeling of nicked DNA by terminal deoxynucleotide transferase, with measurements of cellular DNA content and surface antigens (CD3, CD4, CD8, and CD19) by multiparametric flow cytometry. This assay was used to determine F-ara-A-induced apoptosis in different lymphocyte subsets from CLL patients and normal controls treated with F-ara-A in vitro. Apoptosis was also correlated to bcl-2 protein levels. We observed a direct effect of F-ara-A on both B-CLL and T lymphocytes. The response to F-ara-A in B-CLL lymphocytes in vitro was Rai stage-dependent, the early-stages being more responsive (P = .01). Higher levels of spontaneous apoptosis were observed in B-CLL lymphocytes from early stage patients (P = .02). No difference was observed in spontaneous apoptosis of normal T cells in B-CLL, although T lymphocytes in late-stage disease were more sensitive to F-ara-A-induced apoptosis. Incubation with cyclosporin A did not affect B-CLL and T-lymphocyte survival compared with control cultures. Results suggested a direct apoptotic effect of F-ara-A on B-CLL lymphocytes that decreases with increasing clinical stage. No correlation was found between bcl-2 and spontaneous or F-ara-A-induced apoptosis. Apoptosis occurred at all cell-cycle stages and was not restricted to cells in S phase. The mechanisms of this stage-dependent apoptosis in CLL remain to be elucidated.